HOXA11‑AS induces cisplatin resistance by modulating the microRNA‑98/PBX3 axis in nasopharyngeal carcinoma

Li, Haineng; Huang, Jia; Yu, Sa; Li, Hangbo; Zhou, Yan; Wu, Qingzhong

doi:10.3892/ol.2021.12754

Cited by 11 publications

(8 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liu et al reported that HOXA11-AS contributed to cell proliferation and EMT in hepatocellular carcinoma by regulating the miR-506-3p/Slug axis [ 29 ]. HOXA11-AS increased CDDP resistance by modulating the miR-98/PBX3 axis in nasopharyngeal carcinoma [ 30 ]. In this study, miR-518a was verified as a target of HOXA11-AS.…”

Section: Discussionmentioning

confidence: 99%

RETRACTED ARTICLE: Long non-coding RNA HOXA11 antisense RNA upregulates spermatogenesis-associated serine-rich 2-like to enhance cisplatin resistance in laryngeal squamous cell carcinoma by suppressing microRNA-518a

Shen

Duan

Feng³

et al. 2022

Bioengineered

View full text Add to dashboard Cite

Long noncoding RNAs (LncRNAs) are closely associated with the chemoresistance of laryngeal squamous cell carcinoma (LSCC). Previous studies indicated that HOXA11-AS could function as a vital regulator in human cancers. However, the regulatory mechanisms of HOXA11-AS in the chemoresistance of LSCC remain unclear. In this study, it was found that HOXA11-AS expression was upregulated in cisplatin (CDDP)-resistant LSCC tissues and cells. Loss-of-function assays revealed that HOXA11-AS knockdown inhibited the viability, migration, and invasion, but promoted the apoptosis of CDDP-resistant LSCC cells. Meanwhile, we identified miR-518a as a downstream gene of HOXA11-AS in LSCC, and miR-518a silencing reversed the promotive effect of HOXA11-AS knockdown on CDDP sensitivity of LSCC cells. In addition, miR-518a could inhibit spermatogenesis-associated serine-rich 2-like (SPATS2L) expression by direct interaction, and upregulation of SPATS2L abrogated the inhibitory effect of HOXA11-AS silencing or miR-518a overexpression on CDDP resistance of CDDP-resistant LSCC cells. In sum, our results demonstrated that HOXA11-AS enhanced CDDP resistance of LSCC via miR-518a/SPATS2L axis, which might offer novel therapeutic strategies for CDDP-resistant LSCC.

show abstract

Section: Discussionmentioning

confidence: 99%

RETRACTED ARTICLE: Long non-coding RNA HOXA11 antisense RNA upregulates spermatogenesis-associated serine-rich 2-like to enhance cisplatin resistance in laryngeal squamous cell carcinoma by suppressing microRNA-518a

Shen

Duan

Feng³

et al. 2022

Bioengineered

View full text Add to dashboard Cite

show abstract

“…PBX3 and miR‐1294 3′UTR had complementary sites. Recent evidence has shown that PBX acted as an oncogene and was involved in regulating human malignant tumors, such as nasopharyngeal carcinoma (NPC), 35 ovarian cancer (OC) 36 and GC. 37 PBX3 content was prominently upregulated in GC tissues and cells, which was consistent with previous research.…”

Section: Discussionmentioning

confidence: 99%

Knockdown of hsa_circ_0043691 restrains the progression of gastric cancer by decoying miR‐1294 to target pre‐leukemia transcription factor 3

Gong

Jiang

2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

As the most frequent malignant tumor, gastric cancer (GC) is a major cause of tumor-related death. 1,2 Because of the unconspicuous early symptoms, many GC patients were diagnosed at advanced stages. 3 Although GC can be treated by surgical resection in the clinic, its invasive metastasis greatly increased the difficulty of operation. 4 Thus, it is imperative to investigate the underlying molecular mechanism of GC genesis and progression and develop a new therapeutic regimen.Circular RNA (circRNAs) are characterized by the closed-loop structure and the absence of 5′heads or 3′polyadenylated tail, 5 which made them more stable and resistant to the degradation of exonuclease. 6 Due to the superior characteristics of circRNA, it was found to exert vital effects in the research of new tumor biomarkers. 7 Currently, multiple circRNAs have been found to play an important role in regulating the progress of cell biology in various human diseases. 8,9 Consequently, circRNAs may be promising biomarkers for the management of diverse human diseases.

show abstract

“…Wang et al demonstrated the proliferation of OSCC cells when HOXA11-AS was upregulated, whereas its downregulation increased apoptosis and caspase 3 activity in CDDP-resistant OSCC cells (98). Moreover, HOXA11-AS knockdown inhibited viability, migration, and invasion in LSCC and enhanced cisplatin sensitivity, thus promoting cell apoptosis in NPC tumor tissues (116,117,134).…”

Section: Lncrnas In Hnsccmentioning

confidence: 99%

“…In this regard, OSCC tumor tissues and cell lines were analyzed, concluding that the upregulation of HOXA11-AS promoted proliferation in CDDPsensitive cells and inhibited CDDP-induced cytotoxicity by intervention in the miR214-3p/PIM1 axis (98). Other studies demonstrated that the knockdown of HOXA11-AS enhances CDDP resistance via the miR-98/PBX3 axis (116) and can inhibit the c-Met/AKT/mTOR pathway by specifically upregulating miR-454-3p, thus promoting cell apoptosis and enhancing the sensitivity of cisplatin-resistant NPC cells to cisplatin (117). Conversely, Shen et al analyzed LSCC tissues and cell lines, showing that HOXA11-AS1 knockdown inhibits the viability, migration, and invasion but promotes the apoptosis of cells (134).…”

Section: Foxd2-as1mentioning

confidence: 99%

Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma

et al. 2022

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) originates in the squamous cell lining the mucosal surfaces of the head and neck region, including the oral cavity, nasopharynx, tonsils, oropharynx, larynx, and hypopharynx. The heterogeneity, anatomical, and functional characteristics of the patient make the HNSCC a complex and difficult-to-treat disease, leading to a poor survival rate and a decreased quality of life due to the loss of important physiologic functions and aggressive surgical injury. Alteration of driver-oncogenic and tumor-suppressing lncRNAs has recently been recently in HNSCC to obtain possible biomarkers for diagnostic, prognostic, and therapeutic approaches. This review provides current knowledge about the implication of lncRNAs in drug resistance mechanisms in HNSCC. Chemotherapy resistance is a major therapeutic challenge in HNSCC in which lncRNAs are implicated. Lately, it has been shown that lncRNAs involved in autophagy induced by chemotherapy and epithelial–mesenchymal transition (EMT) can act as mechanisms of resistance to anticancer drugs. Conversely, lncRNAs involved in mesenchymal–epithelial transition (MET) are related to chemosensitivity and inhibition of invasiveness of drug-resistant cells. In this regard, long non-coding RNAs (lncRNAs) play a pivotal role in both processes and are important for cancer detection, progression, diagnosis, therapy response, and prognostic values. As the involvement of more lncRNAs is elucidated in chemoresistance mechanisms, an improvement in diagnostic and prognostic tools could promote an advance in targeted and specific therapies in precision oncology.

show abstract

HOXA11‑AS induces cisplatin resistance by modulating the microRNA‑98/PBX3 axis in nasopharyngeal carcinoma

Cited by 11 publications

References 45 publications

RETRACTED ARTICLE: Long non-coding RNA HOXA11 antisense RNA upregulates spermatogenesis-associated serine-rich 2-like to enhance cisplatin resistance in laryngeal squamous cell carcinoma by suppressing microRNA-518a

RETRACTED ARTICLE: Long non-coding RNA HOXA11 antisense RNA upregulates spermatogenesis-associated serine-rich 2-like to enhance cisplatin resistance in laryngeal squamous cell carcinoma by suppressing microRNA-518a

Knockdown of hsa_circ_0043691 restrains the progression of gastric cancer by decoying miR‐1294 to target pre‐leukemia transcription factor 3

Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma

Contact Info

Product

Resources

About